The European Commission has approved a Type II variation application for Tecvayli (teclistamab), a cell therapy for multiple myeloma developed by Johnson & Johnson's Janssen Pharmaceutical Companies. The approval allows for a reduced dosing frequency in patients who have achieved a complete response for a minimum of six months. The approval was supported by positive results from the Phase 1/2 MajesTEC-1 study. In October 2022, the FDA approved Tecvayli for relapsed or refractory multiple myeloma for patients who previously received four or more prior lines of therapy.